Follitropin delta is a recombinant follicle-stimulating hormone, or FSH, produced in a human cell line, which gives it higher biopotency than earlier recombinant products derived from hamster cells. Because of this increased potency, the drug is measured in micrograms rather than the international units used for other gonadotrophins. When regulators approved it, they endorsed an individualised dosing algorithm that takes a patient’s anti-Müllerian hormone level and body weight into account. That algorithm, however, was validated in gonadotrophin-releasing hormone antagonist protocols culminating in fresh embryo transfer. In freeze-all cycles, where ovarian stimulation is deliberately decoupled from embryo transfer to reduce the risk of ovarian hyperstimulation syndrome and to allow endometrial preparation on the patient’s own timetable, the algorithm’s assumptions no longer hold neatly, and many clinics have found it cumbersome to apply.

The progestin protocol has emerged as an increasingly adopted alternative for freeze-all IVF cycles. Instead of using a GnRH agonist or antagonist to prevent the premature surge of luteinising hormone that could trigger ovulation before egg retrieval, clinicians administer a progestin, a synthetic progesterone-like compound, which suppresses the surge effectively and inexpensively. Combined with the freeze-all strategy, in which all embryos are cryopreserved and transferred in a later, physiologically calmer cycle, the progestin protocol has expanded access to IVF in many settings. Yet no evidence existed on how follitropin delta’s simplified dosing regimens, which had shown promise in antagonist protocols, would perform in this context. The new study set out to fill that gap.

Researchers led by Tien Khac Le of IVFMD Phu Nhuan, My Duc Phu Nhuan Hospital, and colleagues across several Vietnamese institutions conducted a multicentre retrospective cohort study spanning May 2023 to September 2024 at three tertiary hospitals: My Duc Hospital and My Duc Phu Nhuan Hospital in Ho Chi Minh City, and the Family Hospital in Da Nang. They included women undergoing their first IVF or intracytoplasmic sperm injection cycle with a progestin protocol and a freeze-all indication. Patients received either follitropin delta at one of three fixed starting doses of 9, 12, or 18 micrograms per day, or follitropin alfa at 150, 225, or 300 international units per day, with the dose in both groups selected according to the woman’s anti-Müllerian hormone level. This stratified, fixed-dose approach deliberately bypasses the complex individualised algorithm, trading mathematical precision for bedside simplicity.

Because the study was observational rather than randomised, the investigators faced the familiar challenge of confounding: women prescribed one drug might differ systematically from those prescribed the other in age, weight, or ovarian reserve. To address this, they used propensity score matching, a statistical technique that pairs patients from the two treatment groups who share similar baseline characteristics. Matching was performed on age, body mass index, anti-Müllerian hormone, and antral follicle count, the ultrasound-based measure of resting follicles. After matching, 342 women per group were analysed for stimulation and laboratory outcomes, and 315 women in the follitropin alfa group and 314 in the follitropin delta group completed the analysis of their first frozen embryo transfer. The primary outcome was live birth following that first frozen transfer.

The headline result was reassuring equivalence. The live birth rate after the first frozen embryo transfer was 40.1 percent in the follitropin delta group compared with 41.6 percent in the follitropin alfa group, a difference captured by a relative risk of 0.97 with a 95 percent confidence interval of 0.8 to 1.2 and a p value of 0.8. In plain terms, the two regimens produced essentially indistinguishable chances of a baby from the first transfer, and the statistical interval comfortably spans the possibility of no difference at all. For a drug whose potency and dosing logic differ fundamentally from the long-standing standard, that finding carries considerable clinical weight.

Where the regimens diverged was in efficiency. Women receiving follitropin delta completed ovarian stimulation in a median of eight days, compared with nine days in the follitropin alfa group, a difference that was highly statistically significant. Crucially, the shorter stimulation did not come at the cost of follicular yield: the number of follicles measuring at least 14 millimetres and the number of oocytes retrieved were similar between the groups. The authors report that other embryological outcomes, pregnancy outcomes, and neonatal outcomes were also comparable, suggesting that the more potent hormone compressed the stimulation timeline without degrading the quality of the eggs, embryos, or eventual pregnancies that resulted.

Safety findings were equally notable. Not a single case of ovarian hyperstimulation syndrome occurred in either arm of the matched cohort, an outcome that reflects both the freeze-all strategy itself, which removes the pregnancy-driven amplification of the syndrome, and careful dose stratification by ovarian reserve. Ovarian hyperstimulation syndrome remains one of the most feared complications of IVF, and any regimen that maintains live birth rates while keeping that risk at zero in a large cohort will attract attention from clinicians seeking safer stimulation protocols, particularly in settings where high-responder populations are common.

The study’s design does impose limits on how far the conclusions can travel. As a retrospective propensity-matched cohort, it cannot eliminate residual confounding the way a randomised trial would, and the fixed-dose stratification was applied according to local clinical practice rather than a pre-specified protocol. The authors themselves are explicit on this point: while the findings suggest that the pragmatic follitropin delta regimen may offer clinical efficiency in progestin-protocol freeze-all cycles, well-designed prospective randomised controlled trials are required before it can be routinely recommended in clinical practice. The research received no external funding, and the authors declare no competing interests, with ethics approval granted by the Institutional Review Board of My Duc Hospital and patient consent waived given the anonymised, retrospective nature of the data.

Even with those caveats, the study marks a meaningful step in the evolution of personalised ovarian stimulation. Follitropin delta’s individualised algorithm, elegant on paper, has proven difficult to deploy in the protocols that now dominate modern IVF practice, especially freeze-all cycles built on progestin suppression. Demonstrating that a simple three-tier dosing scheme keyed to anti-Müllerian hormone can match the standard drug on live birth while shaving a day off stimulation offers clinics a practical, evidence-grounded option. If randomised trials confirm these results, the microgram-dosed hormone could move from a niche product constrained by its own dosing software to a mainstream tool for ovarian stimulation across the full spectrum of contemporary IVF protocols.

Subject of Research: Follitropin delta dosing for ovarian stimulation in IVF freeze-all cycles using a progestin protocol

Article Title: Novel follitropin delta dosing regimen during in vitro fertilisation using a progestin protocol and freeze-all strategy: a propensity score matching cohort study

Article References: Novel follitropin delta dosing regimen during in vitro fertilisation using a progestin protocol and freeze-all strategy: a propensity score matching cohort study. (n.d.). https://doi.org/10.1186/s13048-026-02292-7

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02292-7

Keywords: follitropin delta, follitropin alfa, IVF, progestin protocol, freeze-all strategy, frozen embryo transfer, ovarian stimulation, anti-Müllerian hormone, live birth rate, ovarian hyperstimulation syndrome, propensity score matching, reproductive medicine

Polycystic ovary syndrome is one of the most common endocrine disorders affecting women of reproductive age, characterized by irregular or absent ovulation, elevated androgens, and polycystic ovarian morphology. Because the hypothalamic-pituitary-ovarian axis behaves differently in these patients, with altered gonadotropin secretion patterns and often exaggerated ovarian sensitivity to hormonal cues, reproductive endocrinologists have debated for decades whether a high baseline LH level helps or harms women undergoing controlled ovarian stimulation. Some earlier hypotheses implicated elevated LH in impaired oocyte quality and reduced implantation, prompting some clinics to suppress LH before treatment. Others argued that LH plays a supportive role in theca cell androgen production, which fuels estradiol synthesis in the granulosa cells that nurture developing follicles. Until now, direct clinical evidence in PCOS patients undergoing modern IVF and intracytoplasmic sperm injection protocols has remained thin.

The research team, led by first authors Jun Liu, Xiaoyu Yu, and Fengjuan Zhang, analyzed records from 162 women with PCOS and 120 controls who all underwent IVF or ICSI followed by embryo transfer at a single reproductive medicine center. To probe whether the starting LH level mattered, the investigators stratified the PCOS patients into high-LH and low-LH groups and then systematically compared their endocrine profiles, ovarian stimulation responses, embryological parameters, endometrial characteristics, and pregnancy outcomes. The ethics committee of Sichuan Provincial Women’s and Children’s Hospital approved the protocol, and all participants provided informed consent, with the study conducted under the Declaration of Helsinki.

The baseline comparisons confirmed the expected metabolic and endocrine signature of PCOS: women with the syndrome had higher body mass index, higher testosterone, and markedly elevated anti-Müllerian hormone, the marker that reflects the enlarged pool of small antral follicles that defines the condition. Yet when it came to the mechanics of stimulation, the two PCOS subgroups diverged in an instructive way. Women in the high-LH group displayed a higher antral follicle count, needed lower total gonadotropin doses to drive multifollicular development, and reached higher estradiol concentrations on the day of the hCG trigger. Together these three signals point in one direction: a higher starting LH level was associated with enhanced ovarian responsiveness, meaning the ovaries of these women answered the stimulation drugs more vigorously and more economically.

Crucially, however, that heightened responsiveness did not translate into better reproductive outcomes. Fertilization rates were statistically indistinguishable between the high- and low-LH PCOS groups, as were embryo quality measures and the proportion of high-quality embryos produced per cycle. The stimulation duration itself was similar across groups, indicating that LH status did not accelerate or delay follicular maturation in any clinically meaningful way. When the investigators tracked the downstream pregnancy endpoints, the pattern held firm: biochemical pregnancy rates, clinical pregnancy rates, and live birth rates showed no significant differences attributable to baseline LH. The hormone that visibly reshaped the stimulation cycle left the bottom line untouched.

To place these subgroup findings in a broader context, the authors applied logistic regression modeling to identify independent predictors of clinical pregnancy across the cohort. The result was striking in what it excluded as much as in what it included. Body mass index and anti-Müllerian hormone emerged as significant independent predictors, while baseline LH failed to reach predictive significance. In practical terms, this means a clinician weighing the prognosis for a PCOS patient about to start an IVF cycle would gain more from noting her weight and her AMH level than from her pre-treatment LH value. The study also flagged a sobering signal on the other side of the pregnancy equation: miscarriage risk was elevated in PCOS patients overall compared with controls, and this risk appeared particularly concentrated in the low-LH subgroup, hinting that insufficient LH activity may be associated with a less favorable early pregnancy environment even if it does not impede conception itself.

What might explain the apparent paradox that LH shapes responsiveness without affecting outcomes? The researchers turned to an animal model for mechanistic insight, establishing a PCOS rat model and examining the ovaries for changes in the expression of the two gonadotropin receptors that orchestrate follicular development: the follicle-stimulating hormone receptor, FSHR, and the luteinizing hormone receptor, LHR. In the granulosa cells, the specialized support cells surrounding each oocyte, the PCOS rats showed a coordinated remodeling of receptor expression, with FSHR decreased and LHR increased. This local shift suggests that under PCOS conditions the ovary recalibrates its sensitivity to the two pituitary hormones, potentially compensating for systemic hormonal disturbances in ways that alter how external stimulation protocols are experienced at the cellular level.

The receptor findings carry implications beyond the laboratory. If granulosa cells in PCOS ovaries downregulate FSHR while upregulating LHR, the conventional assumption that FSH-driven stimulation proceeds through the same molecular machinery in PCOS and non-PCOS ovaries becomes questionable. Elevated local LHR expression could partly explain why high-LH PCOS patients respond so exuberantly to exogenous gonadotropins, achieving robust estradiol rises with lower drug doses. At the same time, the dysregulation of this local signaling network may contribute to the disordered folliculogenesis that characterizes the syndrome, and could interact with the elevated miscarriage risk the study documented, though the authors are careful to present the animal data as suggestive of dysregulated gonadotropin signaling rather than proof of a specific causal chain running from receptor expression to pregnancy loss.

For patients, the clinical takeaway is genuinely liberating. Women with PCOS who discover a high LH value on their pre-treatment blood panel need not fear that this number has doomed their cycle, nor should those with low LH assume their chances are compromised at the outset. The study indicates that baseline LH in PCOS is a marker of ovarian responsiveness, useful perhaps for tailoring gonadotropin starting doses and anticipating hyper-response, but not a determinant of fertilization, implantation, clinical pregnancy, or live birth. Meanwhile, the identification of BMI and AMH as independent predictors reinforces what a growing body of literature has argued: weight management and ovarian reserve assessment deserve central places in fertility counseling for PCOS patients. Elevated AMH, though it reflects the abundant follicle pool that makes PCOS ovaries so responsive, emerged alongside BMI as a predictor of clinical pregnancy, underscoring the complex double-edged role this hormone plays in the syndrome.

As with all retrospective single-center studies, the findings come with caveats that invite future work. The cohort of 282 participants is substantial but retrospective design cannot exclude residual confounding, and stimulation protocols, laboratory conditions, and transfer strategies may vary across centers and eras. Nonetheless, the study’s dual design, combining a well-stratified clinical cohort with mechanistic receptor analysis in an animal model, gives it unusual breadth for the field. By demonstrating that the luteinizing hormone value on a pre-treatment lab slip tells a story about ovarian sensitivity but not about babies, the Chengdu team has helped refocus attention on the factors that truly move the needle for women with PCOS pursuing assisted reproduction, while opening a fresh line of inquiry into how the ovary’s own receptor landscape rewires itself in one of the most common hormonal disorders of our time.

Subject of Research: The effect of basal luteinizing hormone levels on IVF/ICSI-ET outcomes in women with polycystic ovary syndrome

Article Title: Effect of basal luteinizing hormone on IVF/ICSI-ET outcomes in patients with polycystic ovary syndrome: a retrospective study

Article References: Liu, J., Yu, X., Zhang, F., Liu, W., Zeng, J., & Wang, L. (2026). Effect of basal luteinizing hormone on IVF/ICSI-ET outcomes in patients with polycystic ovary syndrome: a retrospective study. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02603-5

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02603-5

Keywords: polycystic ovary syndrome, luteinizing hormone, IVF, ICSI, embryo transfer, anti-Müllerian hormone, ovarian stimulation, live birth rate, miscarriage risk, granulosa cells, FSHR, LHR

The findings, drawn from nine randomized controlled trials encompassing 2,481 women with recurrent implantation failure, are cautiously encouraging. The researchers, led by Mohammadamin Parsaei of Tehran University of Medical Sciences, found that women whose embryos underwent laser-assisted hatching had significantly higher rates of clinical pregnancy, ongoing pregnancy, and live birth compared with women who received no such intervention. Perhaps most strikingly, the technique was associated with a significantly lower rate of miscarriage, and the live birth and miscarriage results carried moderate certainty in the researchers’ formal quality assessment, a level of confidence that is rare in this literature.

To understand why the technique exists at all, one has to look at the biology of the earliest days of embryonic development. Every embryo begins life encased in the zona pellucida, a glycoprotein shell that protects the oocyte and early embryo, mediates sperm recognition, and prevents premature implantation. As the embryo reaches the blastocyst stage, it must hatch from this shell, expanding, contracting, and finally rupturing it before it can make contact with the uterine lining. Scientists have long hypothesized that some embryos, particularly those cultured in the laboratory or derived from older oocytes with hardened or thickened zonae, may struggle to complete this escape, and that a laboratory-assisted exit could tip the balance toward successful implantation.

Assisted hatching began as a micromanipulation procedure in the late 1980s, when researchers first partially opened the zona pellucida to facilitate fertilization and later to aid hatching. Early methods relied on mechanical piercing or acidic chemical drilling, both of which carried risks of embryo damage and required considerable manual skill. The introduction of non-contact diode and ultraviolet lasers in the 1990s transformed the procedure: a focused beam could now thin a precise section of the shell, or drill a controlled opening, in seconds, with minimal handling and reproducible results. Today, laser-assisted hatching is performed in two main variants, zona thinning and zona drilling, and the new analysis examined both approaches in its subgroup analyses.

For the new study, the team searched PubMed, Web of Science, Scopus, and Embase on January 22, 2025, for randomized controlled trials comparing embryo transfer outcomes after laser-assisted hatching against controls specifically in women with recurrent implantation failure. They followed the PRISMA 2020 reporting guidelines, assessed risk of bias with the Cochrane RoB 2 tool, pooled outcomes using random-effects meta-analyses expressed as log odds ratios, and graded the certainty of the evidence with the GRADE framework. Publication bias was probed with funnel plots, Egger’s regression test, and the trim-and-fill method, while subgroup analyses stratified results by mean patient age, overall risk of bias, and the specific hatching technique used.

The headline numbers tell a consistent story. Clinical pregnancy was significantly more likely in the hatched group, with a log odds ratio of 0.643 and a 95 percent confidence interval of 0.267 to 1.019, though the underlying trials showed substantial heterogeneity and the certainty of this evidence was rated very low. Ongoing pregnancy showed a similar pattern, with a log odds ratio of 0.811 and very low certainty. Live birth, the outcome that matters most to patients, was significantly improved with a log odds ratio of 0.519 and remarkably low heterogeneity between studies, earning a moderate certainty rating. Miscarriage was significantly reduced, with a log odds ratio of minus 0.632, zero heterogeneity, and moderate certainty.

Not every result favored the intervention. Implantation rates per transferred embryo did not differ significantly between groups, with a log odds ratio of 0.691 whose confidence interval crossed zero and very high heterogeneity of 87.14 percent, suggesting the trials measured this outcome in markedly different ways. Multiple pregnancy rates per clinical pregnancy were also statistically indistinguishable between groups, with zero heterogeneity and moderate certainty, a finding that will reassure clinicians who have worried that weakening the zona pellucida might encourage the embryo to split into identical twins.

The divergence between the live birth and miscarriage results on one hand and the implantation result on the other is scientifically intriguing. If laser-assisted hatching does not measurably increase the proportion of embryos that implant, yet more pregnancies ultimately end in a take-home baby and fewer end in miscarriage, one possible interpretation is that the technique benefits embryos that would otherwise implant abnormally or fail shortly after attachment. The authors themselves, however, urge restraint, noting that the heterogeneity observed across trials and the generally low quality of the available studies mean these conclusions remain provisional, and that high-quality, large-scale randomized controlled trials are needed to confirm them.

The new analysis arrives amid a shifting regulatory and clinical landscape. The American Society for Reproductive Medicine’s 2022 guideline on assisted hatching concluded that the procedure should not be offered routinely or even as a treatment for patients with an anticipated poor prognosis, citing insufficient evidence of benefit. A 2021 Cochrane review of assisted hatching across all IVF and ICSI patients similarly found no clear benefit and raised concerns about possible harms. Yet those syntheses pooled broad populations, including many patients with no implantation problems at all, which may have diluted any genuine effect in the subgroup that matters. By restricting the analysis to women with documented recurrent implantation failure, the new study tests a more focused hypothesis, and its positive live birth finding stands in meaningful tension with the earlier, broader reviews.

For the roughly ten percent of IVF patients who experience repeated implantation failure, the practical takeaway is one of measured hope rather than a change in standard care. The evidence now suggests that laser-assisted hatching, a quick and technically straightforward laboratory procedure, may improve the odds of a live birth in this difficult population without increasing multiple pregnancies, and that it may reduce the heartbreak of miscarriage. But with several of the key outcomes graded at very low certainty, and with the field still lacking a universally agreed definition of recurrent implantation failure itself, patients and clinicians alike will be watching for the large, well-designed trials that the authors say are now essential. Until then, the laser remains a promising but unproven ally in one of fertility medicine’s most stubborn challenges.

Subject of Research: Laser-assisted hatching and embryo transfer outcomes in patients with recurrent implantation failure

Article Title: Outcomes of Embryo Transfer Following Laser-assisted Hatching in Patients with Recurrent Implantation Failure: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Article References: Parsaei, M., Karimi, E., Seifi, P., Dehghan Tarzjani, M., & Tarafdari, A. (2026). Outcomes of Embryo Transfer Following Laser-assisted Hatching in Patients with Recurrent Implantation Failure: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Reproductive Sciences. https://doi.org/10.1007/s43032-026-02219-z

Image Credits: AI Generated

DOI: 10.1007/s43032-026-02219-z

Keywords: laser-assisted hatching, recurrent implantation failure, embryo transfer, in vitro fertilization, meta-analysis, live birth rate, miscarriage, zona pellucida, clinical pregnancy, assisted reproductive technology, randomized controlled trials, reproductive medicine

The study, led by Emily A. Clarke of the Icahn School of Medicine at Mount Sinai and Reproductive Medicine Associates of New York, together with colleagues including Alan B. Copperman, examined 203 patients who experienced early pregnancy loss and subsequently underwent a single euploid embryo transfer, a procedure in which a genetically screened embryo with the correct number of chromosomes is transferred one at a time. Of these patients, 88 were managed medically, typically with misoprostol, while 115 underwent surgical management, usually dilation and curettage. Because all participants received embryos confirmed to be chromosomally normal through preimplantation genetic testing, the researchers were able to isolate the contribution of the uterine environment itself, removing the confounding noise of embryo aneuploidy, which is the leading cause of early miscarriage and failed implantation.

The primary outcome was the change in endometrial thickness between the cycle in which the pregnancy was lost and the subsequent frozen embryo transfer cycle. Endometrial thickness, measured by transvaginal ultrasound, is one of the most closely watched parameters in reproductive medicine because a lining thinner than seven millimeters is associated with markedly reduced implantation and live birth rates. Large analyses of tens of thousands of embryo transfers, including a 2022 study of more than 96,000 autologous transfers published in Fertility and Sterility, have demonstrated a graded relationship between lining thickness and success, making any iatrogenic thinning of the endometrium a legitimate clinical concern.

What the researchers found was striking in its neutrality. Between the initial and subsequent transfer cycles, endometrial thickness changed by an average of plus 0.3 millimeters in the medically managed group and plus 0.1 millimeters in the surgically managed group, a difference that was statistically indistinguishable with a P value of 0.65. In the subsequent transfer cycle itself, the average lining measured 9.4 millimeters in the medical group and 9.1 millimeters in the surgical group, again with no significant difference. Cycle cancellation because of a persistently thin lining, defined as less than seven millimeters, was rare in both arms, occurring in 3.4 percent of medically managed patients and 2.6 percent of surgically managed patients. In practical terms, the surgical instrumentation that many feared might scar the uterine cavity did not measurably impair the endometrium’s ability to proliferate under hormonal preparation.

This finding carries particular weight because prior literature had raised genuine alarms. Earlier studies, including work by Shufaro and colleagues in 2008 and investigations by Davar and Azumaguchi, described a thin, unresponsive endometrium as a possible complication of surgical curettage, with some patients developing linings that failed to thicken even with high doses of estrogen. Asherman’s syndrome, the formation of intrauterine adhesions after aggressive curettage, remains a recognized and sometimes devastating consequence of uterine instrumentation. The new data do not erase those risks, which are uncommon but real, yet they suggest that in the specific population of IVF patients destined for euploid embryo transfer, routine dilation and curettage for early pregnancy loss does not produce a detectable average penalty on endometrial development.

The secondary outcomes told a more nuanced story. While live birth rates in the subsequent transfer cycle were statistically similar between the two groups, 48.8 percent among medically managed patients versus 40.7 percent among surgically managed patients, the rate of clinical pregnancy loss after a positive pregnancy test was significantly higher in the surgical cohort, at 15.7 percent compared with 4.9 percent. After adjusting for potential confounders, surgical management carried an adjusted odds ratio of 3.72 for subsequent pregnancy loss, with a 95 percent confidence interval of 1.11 to 12.47. The authors stopped short of claiming causation, and the absolute difference, roughly eleven percentage points, is modest, but the signal is biologically plausible. Instrumentation of the uterine cavity could theoretically alter the endometrium’s receptivity at a level finer than thickness alone can capture, affecting the molecular dialogue between embryo and lining that governs implantation and placentation.

Endometrial receptivity is a complex process involving the synchronized expression of hundreds of genes, the maturation of the epithelial pinopodes, the recruitment of immune cells, and the development of an adequate blood supply. Research into implantation failure has implicated inflammatory markers and disruptions of this delicate immunological environment. A curettage procedure induces a controlled injury and an inflammatory repair response, and while the lining may regenerate to a normal thickness, subtle alterations in its functional quality could persist. The elevated miscarriage rate observed in the surgical group, despite equivalent lining measurements and equivalent live birth rates among those pregnancies that did progress, hints at exactly this kind of subclinical functional difference, one that ultrasound cannot see but that may manifest as an early pregnancy that implants and then fails.

The study’s design deserves scrutiny. As a single-center retrospective cohort, it cannot randomize patients to treatment arms, and the choice between medical and surgical management was made by patients and physicians based on clinical circumstances, introducing the possibility of selection bias. Patients with heavier bleeding, retained tissue, or hemodynamic instability are more likely to undergo surgery, and these same factors might independently affect subsequent reproductive outcomes. The sample size of 203, while respectable for a single-center study, limits statistical power for rare outcomes, and the wide confidence interval around the miscarriage odds ratio reflects that uncertainty. Nevertheless, the use of euploid single embryo transfers represents a methodological strength that few prior studies on this question have enjoyed, because it controls for the single largest determinant of IVF success, namely embryo chromosomal competence.

For clinicians, the findings translate into a more evidence-based framework for counseling. Patients with early pregnancy loss who have frozen euploid embryos waiting can be told that neither medical nor surgical management appears to compromise their endometrial thickness or their overall chances of a live birth in the next transfer cycle. Those who prefer the certainty and speed of a surgical procedure, or who require it for clinical reasons, can be reassured that the lining typically recovers fully. At the same time, the elevated loss rate in the surgical group gives clinicians a legitimate data point to discuss, particularly for patients with a history of recurrent pregnancy loss who may be especially sensitive to any factor that raises miscarriage risk. The decision should remain individualized, weighing the efficacy, side effects, and completion rates of misoprostol against the operating room requirements of curettage.

The research, presented orally at the American Society for Reproductive Medicine’s scientific congress in Denver in October 2024 before its peer-reviewed publication, adds to a growing body of work aimed at demystifying what happens to the uterus after miscarriage and how best to prepare it for the next attempt. Early pregnancy loss affects roughly one in ten recognized pregnancies, and among IVF patients the emotional and financial stakes of each subsequent cycle are exceptionally high. By demonstrating that endometrial recovery is robust across both management pathways, and by flagging a modest but significant difference in subsequent pregnancy loss, the study gives patients and physicians something they have long lacked: quantitative, embryo-quality-controlled evidence on which to base one of the most common and consequential decisions in reproductive medicine. The authors note that de-identified data are available upon reasonable request, and they emphasize that these findings may help guide counseling for patients navigating the difficult intersection of miscarriage management and fertility treatment.

Subject of Research: How medical versus surgical management of early pregnancy loss affects endometrial thickness and outcomes of subsequent euploid embryo transfers in IVF patients

Article Title: Management of Early Pregnancy Loss: Reproductive Outcome in Subsequent Euploid Embryo Transfers

Article References: Management of Early Pregnancy Loss: Reproductive Outcome in Subsequent Euploid Embryo Transfers. (n.d.). https://doi.org/10.1007/s43032-026-02200-w

Image Credits: AI Generated

DOI: 10.1007/s43032-026-02200-w

Keywords: early pregnancy loss, dilation and curettage, misoprostol, endometrial thickness, euploid embryo transfer, in vitro fertilization, live birth rate, clinical pregnancy loss, reproductive medicine, miscarriage management, Management, Early